ppardelta agonist 2

Dopamine D2 receptor agonist-2 (Dopamine D2 Receptor) is a ligand targeting the dopamine D2 receptor.

TREM2 agonist-2 (I-192) is an orally active and potent myeloid triggered receptor 2 (TREM2) agonist for the study of neurodegenerative diseases.

S1R agonist 2 is a selective S1R agonist with a Ki of 88 nM for S2R and 1.1 nM for S1R and is protective against ROS and NMDA-induced neurotoxicity.

β2AR/M-receptor agonist-2 is a dual-function compound acting as a muscarinic antagonist and β2 adrenoceptor agonist (MABA). It demonstrates significant activity towards the β2 adrenoceptor with an EC50 of 3.7 nM and exhibits affinity for the human cloned M3 receptor with a Ki of 0.73 nM. This potent bronchodilator holds potential for research in chronic obstructive pulmonary disease (COPD) treatment.

HIF-2α agonist 2 is an HIF-2α agonist with an EC50 value of 1.68 μM for HIF-2α. HIF-2α agonist 2 can promote the stability of the ARNT A/B ring in the 3z structure of HIF-2a-ARNT complex without cytotoxicity to 786-o-Reha-Luc cells. HIF-2α agonist 2 can be used in the study of oxygen metabolism and is closely related to the occurrence of cancer.

GPR35 agonist 2 (TC-G 1001) is a potent GPR35 agonist.The EC50 values of GPR35 agonist 2 in the β-arrestin and Ca2+ release assays were 26 and 3.2 nM, respectively.

CB2 receptor agonist 2 (ZINC72105556) is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor, Ki = 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2.

TLR7 agonist 2 (TLR7-IN-1) is a specific and effective Toll-like Receptor 7 (TLR7) agonist (LEC=0.4 μM).

Compound 28.1, also known as TAS2R14 agonist-2, is a potent and selective inhibitor of TAS2R14, exhibiting an EC50 of 72 nM [1].

Compound 40 is a selective M1/M4 muscarinic antagonist with an IC50 of 19 nM for M1 receptors and 42 nM for M4 receptors [1].

Cisd2 agonist 2 (compound 6), with an EC50 of 191 nM, is an orally active activator of Cisd2, a protein whose levels are associated with nonalcoholic fatty liver disease (NAFLD). In vivo studies have demonstrated that Cisd2 agonist 2 exhibits no significant toxicity in heterozygous hepatocyte-specific Cisd2 knockout (Cisd2hKO-het) mice [1].

GPR139 agonist-2 (compound 20a), a potent GPR139 agonist with an EC50 of 24.7 nM, has demonstrated efficacy in rescuing social interaction deficits and alleviating cognitive deficits in murine schizophrenia models, indicating its potential in antischizophrenia drug research [1].

GPR120 Agonist 2 is a potent and selective GPR120 receptor agonist.

Y4R Agonist-2 is a potent agonist of the Y4 receptor, exhibiting a K_i value of 0.033 nM.

Orexin 2 Receptor Agonist (OX2R) is an effective (EC50: 23 nM) and OX2R-selective (OX1R/OX2R EC50 ratio: 70) agonist.

Glucocorticoid receptor agonist-2 Ala-Ala-Mal (compound 79) serves as a precursor for synthesizing anti-inflammatory antibody-drug conjugate (ADC) molecules and acts as an active reference for ABBV-3373 [1].

NLRP3 agonist 2 (compound 22) is an orally active agent that activates Caspase-1 in THP1 cells [1].

GPCR agonist-2 (4-(Cyclopropylamino)-3-nitrobenzoic acid) is an agonist of the orphan human GPCR GPR109B.

RXFP1 Receptor Agonist-2 (Example 124), an EC50 value of 1 nM [1].

GPR3 agonist-2 (compound 32) is a potent full agonist of the G protein-coupled receptor 3 (GPR3), exhibiting an IC50 value of 260 nM [1].

CB2R agonist 2 (cis-17-para) is a CB2R agonist [1].

Pparδ agonist 2 is an agonist of PPARδ.

GPR40 Agonist 2 is a GPR40 agonist. It can be used in the research of diabetes.

GPR81 agonist 2 is a potent agonist targeting the GPR81 receptor, demonstrating EC50 values of 0.023 µM for hGPR81 and 0.123 µM for hGPR109A, respectively.

Glucocorticoid receptor agonist-2 (compound 21), a glucocorticoid receptor agonist exhibiting an IC50 value of 6.6 nM, serves as an active reference for ABBV-3373 [1]. This compound is instrumental in the synthesis of anti-inflammatory ADC molecules.

ERRγ agonist-2 is a potent and selective ERRγ inverse agonist with a K d value of 6.5 μM. ERRγ agonist-2 inhibits the expression of hepcidin, fibrinogen and gluconeogenic genes. ERRγ agonist-2 has antimicrobial, anti-coagulant and antidiabetic activities [1] .

CB1/2 agonist 4 (compound 24) is a CB1 full agonist (EC50: 15.09 nM) and a CB2 partial agonist (EC50: 1.16 nM). CB1/2 agonist 4 has significant anti-harm-sensing activity and also activates cannabinoid and TRPV1 receptors (IC50: 0.8 μM, EC50: 0.12 μM). , EC50: 0.12 μM).

FPR2 agonist 2 is a potent FPR2 agonist with blood-brain barrier permeability that acts on h-FPR2 (EC50: 0.13 nM). fPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counteracts changes in mitochondrial function, and inhibits caspase-3 activity.

Orexin 2 Receptor Agonist 2 (ORA-2) is a specific agonist for the orexin 2 receptor.

TRβ agonist 2 (Compound 1) is a highly potent agonist of TRβ. Moreover, it effectively reduces lipid accumulation in HepG2 cells and promotes lipolysis, offering comparable effects. With its promising attributes, TRβ agonist 2 emerges as a potential thyromimetics that selectively targets TRβ [1].

GPR119 agonist 2 (compound 43), an orally active agonist of GPR119, exhibits favorable pharmacokinetic properties in rodents and has demonstrated efficacy in enhancing glucose tolerance in both mice and rats, indicating its potential in type 2 diabetes research [1].

PPARγ agonist 2 is a highly effective compound that acts as a partial agonist for PPARγ. It exhibits significant potential for utilization in metabolic disease research [1].

5-HT2A receptor agonist-2 is a potent compound that acts as an agonist on the serotonin 5-HT2 receptor. It specifically stimulates the 5-HT 2A, 5-HT 2B, and 5-HT 2C receptors, with EC 50 values of 1.7 nM, 0.58 nM, and 0.50 nM, respectively [1].

Glucocorticoid receptor agonist 2 is a highly effective anti-inflammatory compound, derived from arylpyrazole, that actively binds to and activates the glucocorticoid receptor. This compound exhibits potent anti-inflammatory properties without disrupting insulin secretion.

CBR Agonist-2 is a CB1 agonist (CB1R; CB1 ligand) (EC50: 960 nM, Ki: 970 nM). CBR Agonist-2 is a promising tool for the study of endogenous cannabinoid system-related diseases involving hCB1R.

Adenylyl cyclase type 2 agonist-1 is a potent agonist of adenylyl cyclase type 2 (AC2) (EC50: 90 nM). It is a potential lead compound in the fight against respiratory diseases.

AhR agonist 2 (Compound 12a) is a highly potent agonist of the aryl hydrocarbon receptor (AhR), exhibiting an EC50 value of 0.03 nM. This compound rapidly induces nuclear enrichment of AhR and initiates transcription of downstream genes, thereby promoting skin barrier repair. AhR agonist 2 shows promising potential for psoriasis research [1].

Compound 5, a selective GPR109a agonist, exhibits a pEC50 value of 5.53 [1].

EP4 receptor agonist 2 (compound 31) is a potent EP4 receptor agonist, demonstrating an EC50 value of 0.8 nM and K_i values of >100,000, 38,000, and 3.1 nM for the EP2, EP3, and EP4 receptors, respectively [1].

RXFP3/4 agonist 2 is a potent non-peptidic bis-RXFP3/4 agonist that induces the interaction between RXFP3 and β-arrestin-2, and can be used to study diseases caused by metabolic abnormalities.

CB1 Inverse Agonist 2, an orally active compound, serves as an inverse agonist for the Cannabinoid Receptor CB1. It effectively counteracts the hypothermia and anorexia induced by CP55940 in mouse models.

TGR5 agonist 2 (compound 19) serves as a highly potent agonist of TGR5, demonstrating an EC50 value of 0.27 µM [1].

S1p receptor agonist 2 (compound 1) is an agonist of the S1P5 receptor with a higher selectivity than S1P1 and/or S1P3 receptors.S1p receptor agonist 2 can be used in the endogenous SIP signaling system and in the mitigation/prevention of central nervous system (CNS) diseases such as neurodegenerative diseases. .

Compound 8, identified as a selective alpha4beta2 (α4β2) neuronal acetylcholine receptor (nAChR) agonist, demonstrates a dissociation constant (Kd) of 26 nM, indicating high affinity for this receptor subtype.

5-HT7 agonist 2 is a highly potent 5-HT7 receptor agonist, exhibiting an IC50 value of 28.7 nM. This compound holds promise for studying and understanding various Central Nervous System (CNS) disorders [1].

Ghrelin receptor full agonist-2 is a highly potent Ghrelin receptor full agonist.

S1PR1 agonist 2 is a potent agonist of S1PR1. S1PR1 agonist 2 has potential for studies of autoimmune diseases.

CB1/2 agonist 2 (compound 23) is a potent non-selective cannabinoid ligand with Ki of 3.5 nM and 1.2 nM, respectively. CB1/2 agonist 2 is a full agonist of CB1 and a competitive inverse agonist of CB2. BACE-IN-1 is a complete agonist of CB1 and a competitive inverse agonist of CB2.

μ opioid receptor agonist 2 （Compound H-3）is a MOR receptor agonist. μ opioid receptor agonist 2 can be used for the research of pain and pain related diseases.

BMP agonist 2 has up-regulated bone morphogenetic protein BMP-2 expression activity in vivo and anti-osteoporosis effects, and also has ameliorated the symptoms of osteoporosis in SAMP6 mice.BMP agonist 2 is an osteoinductive cytokine that promotes the production of bone tissue, and can be used in the study of senile osteoporosis (SOP).